MCK stock forecast, quote, news & analysis

Key Takeaways

• MCK climbed about 16.5% over the last 30 days, rising from $853.81 on September 30 to $994.58 at the October 30 close.
• The extension of McKesson's pharmaceutical distribution agreement with CVS Health through June 2032 removed a key contract overhang and drove a sharp early-October advance.
• A wave of analyst price-target increases — including several targets of $1,200 or higher — reinforced positive sentiment during the month.
• The stock set a 52-week high of $1,030.12 on October 20 before easing back in the final sessions of the month.
• Continued strength in oncology, specialty distribution, and GLP-1 medication volumes underpins McKesson's earnings momentum.
• McKesson is scheduled to report fiscal second-quarter results on November 4, with consensus estimates near $10.69 per share.
• For more detail on analyst expectations, explore McKesson's Price Targets, Earnings, and Forecast pages.
• Discover AI-driven trading strategies across thousands of tickers by exploring Trending AI Robots.

McKesson (MCK) Company Overview and Market Position

McKesson Corporation is a diversified healthcare services company and one of North America's largest pharmaceutical distributors. Founded in 1833 and headquartered in Irving, Texas, the company operates through four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. With a market capitalization of roughly $116 billion and trailing 12-month revenue of about $411 billion, McKesson is a core holding for investors focused on healthcare services.

Beyond traditional drug distribution, McKesson has been repositioning toward higher-margin specialty capabilities, including oncology networks, biopharma services, and technology-enabled access solutions. Its scale across retail pharmacies, health systems, and provider networks, combined with competitors such as Cardinal Health and Cencora, gives McKesson a central role in the pharmaceutical supply chain that investors track closely.

McKesson (MCK) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, MCK advanced from a September 30 close of $853.81 to $994.58 on October 30, a gain of roughly 16.5%. The move was not a straight line: shares surged in early October after the CVS Health distribution extension, continued climbing through mid-month, and reached a 52-week high of $1,030.12 on October 20 before pulling back about 3% into month-end.

The broader three-month trend has been similarly strong. From a close near $827 in early August, the stock has risen roughly 20% through late October, reflecting sustained investor confidence in McKesson's specialty-focused growth strategy rather than a single short-term catalyst.

What Drove MCK Stock Price in the Last 30 Days

The most significant single catalyst came on October 1, when McKesson announced an agreement in principle with CVS Health to extend its pharmaceutical distribution relationship across mail-order, specialty, retail, and distribution-center channels through June 2032. The shares jumped about 5.3% on the news, as the long-dated agreement provided clarity on a major customer relationship and removed a lingering overhang.

Analyst activity added further support. Morgan Stanley raised its price target to $1,207 from $977, UBS lifted its target to $1,200 from $1,080, and Mizuho increased its target to $1,020 from $905. Leerink Partners maintained a Buy rating with a $1,070 target, while Deutsche Bank reiterated a Buy with a $913 target. Separately, McKesson and Clayton Dubilier & Rice agreed to acquire Option Care Health in a transaction valued near $5.8 billion, with McKesson committing roughly $1.4 billion for a 49% stake. The company also received a $741.5 million Defense Logistics Agency contract and declared a regular quarterly dividend of 94 cents per share.

What Drove MCK Stock Performance Over the Last Quarter

McKesson's quarterly strength reflects a longer-running narrative: the company's transformation from a low-margin distributor into a higher-margin, specialty-focused healthcare services platform. In its most recent reported quarter, ended June 30, 2026, McKesson posted revenue of $105.38 billion, and management indicated that adjusted earnings per share rose about 20% year over year.

Growth has been concentrated in oncology and multispecialty services, biopharma solutions, and prescription technology, supported by acquisitions such as the Precision Medicine Group transaction and the PRISM Vision and Core Ventures deals. Distribution volumes for GLP-1 medications and specialty pharmaceuticals have added further momentum. The planned separation of the Medical-Surgical Solutions business and disciplined share-repurchase programs have reinforced the case for durable earnings growth over multiple quarters.

Trending AI Robots

Tickeron offers hundreds of AI trading bots that actively trade thousands of tickers, but only the top-performing and most relevant strategies are surfaced in its curated Trending AI Robots section. These bots vary widely in approach, timeframe, and performance metrics, allowing traders to compare momentum, trend-following, and pattern-recognition strategies side by side. The section is designed to help investors identify automated approaches that align with their own risk tolerance and trading style. Investors evaluating healthcare names such as McKesson can browse the selection to see which AI-driven strategies are currently gaining traction.

MCK Stock Forecast Drivers: What Investors Should Watch Next

The next major milestone is McKesson's fiscal second-quarter earnings report on November 4, when the company is expected to report earnings near $10.69 per share on revenue of roughly $110.11 billion. Investors will focus on management's full-year guidance, commentary on specialty and GLP-1 volumes, and any updates on the Option Care Health transaction and the Medical-Surgical Solutions separation.

Broader factors to monitor include drug-pricing policy and regulatory scrutiny, pharmacy benefit channel dynamics, and competitive pressures from Cardinal Health and Cencora. Analyst consensus on MCK remains firmly positive, with an average price target near $1,026, though execution risk around acquisitions and portfolio separation warrants continued attention.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations